Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammatory protein epigenetic scores (EpiScores) and cognitive function in the longitudinal Swedish adoption/twin study of aging (SATSA).

GeroScience·2026
Same author

A Device-Free Respiratory Gating Technique for Dynamic CT Using Time-Density Curve Analysis: A Technical Report With Clinical Applications.

Cureus·2026
Same author

Epidemiologic and clinicopathologic features of 19,352 jaw cysts: a single-center retrospective study.

BMC oral health·2026
Same author

Oral, Vaginal, and Placental Microbiota Profiles in Japanese Pregnancies with Preterm Birth and Chronic Abruption-Oligohydramnios Sequence (CAOS): A Cross-Sectional Study.

Medicina (Kaunas, Lithuania)·2025
Same author

Bone Morphogenetic Protein 7 Promotes the Differentiation of Periodontal Ligament Fibroblasts into F-Spondin-Expressing Cementoblast-like Cells During Root Canal Treatment-An In Vivo Rat Pulpectomy Model and In Vitro Human Fibroblast Study.

Dentistry journal·2025
Same author

SigH of Porphyromonas gingivalis Regulates Oxidative Stress Resistance and Invasion of Oral Epithelial Cells.

The Bulletin of Tokyo Dental College·2025

Related Experiment Video

Updated: Jul 13, 2026

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

Controlled release of simvastatin acid using cyclodextrin inclusion system.

Masao Yoshinari1, Kenichi Matsuzaka, Sadamitsu Hashimoto

  • 1Oral Health Science Center HRC7, Tokyo Dental College, 1-2-2 Masago, Mihama-ku, Chiba 261-8502, Japan. yosinari@tdc.ac.jp

Dental Materials Journal
|August 19, 2007
PubMed
Summary

Simvastatin acid (SVA) release from titanium coatings is slower at lower pH. This is due to increased crystallinity of simvastatin acid/cyclodextrin (SVA/CD) complexes, impacting bone formation applications.

More Related Videos

Transport Properties of Ibuprofen Encapsulated in Cyclodextrin Nanosponge Hydrogels: A Proton HR-MAS NMR Spectroscopy Study
10:10

Transport Properties of Ibuprofen Encapsulated in Cyclodextrin Nanosponge Hydrogels: A Proton HR-MAS NMR Spectroscopy Study

Published on: August 15, 2016

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles
09:57

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles

Published on: December 23, 2016

Related Experiment Videos

Last Updated: Jul 13, 2026

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

Transport Properties of Ibuprofen Encapsulated in Cyclodextrin Nanosponge Hydrogels: A Proton HR-MAS NMR Spectroscopy Study
10:10

Transport Properties of Ibuprofen Encapsulated in Cyclodextrin Nanosponge Hydrogels: A Proton HR-MAS NMR Spectroscopy Study

Published on: August 15, 2016

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles
09:57

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles

Published on: December 23, 2016

Area of Science:

  • Biomaterials Science
  • Drug Delivery Systems
  • Nanotechnology

Background:

  • Simvastatin acid (SVA) promotes osteoblast differentiation and bone formation via BMP-2.
  • Cyclodextrins (CDs) form inclusion complexes, enhancing drug solubility and stability.
  • SVA/CD complexes offer potential for localized drug delivery in bone regeneration.

Purpose of the Study:

  • To investigate the pH-dependent release kinetics of SVA from SVA/CD complexes coated on titanium.
  • To characterize the physical properties of SVA/CD complexes at varying pH.
  • To correlate SVA release rates with the crystallinity of SVA/CD coatings.

Main Methods:

  • Preparation of SVA/CD inclusion complex solutions at different pH values.
  • Coating of SVA/CD solutions onto titanium substrates.
  • In vitro assessment of SVA release kinetics from coated titanium.
  • Analysis of SVA/CD complex crystallinity using relevant techniques.

Main Results:

  • Lower pH values of the SVA/CD solutions resulted in significantly reduced SVA release rates.
  • Increased pH decrease correlated with a higher degree of crystallinity in the SVA/CD complexes within the coatings.
  • A direct relationship was observed between solution pH, complex crystallinity, and SVA release kinetics.

Conclusions:

  • The release rate of SVA from titanium coatings is modulated by the pH of the SVA/CD complex solution.
  • Coating crystallinity, influenced by pH, is a critical factor governing SVA release kinetics.
  • Controlled SVA release can be achieved by optimizing solution pH for enhanced bone regeneration therapies.